

April 25, 2024

Subject: Letter of Support for CIRM Grant #TRAN1-16065

Dear Members of the Application Review Subcommittee,

I am writing today in support of Grant #TRAN1-16065 (A Novel Gene Therapy to Target Glioblastoma via Custom-Engineered Adenovirus-Associated Viral Vectors). I would urge you to fully fund this important research, which will hopefully lead to a direct benefit for patients.

GBM is a devastating disease with essentially no effective treatments today. As a biotech investor, I've seen many companies and entrepreneurs looking to fund potential solutions. It is a challenging space for biotech investors because the clinical failure rate is high, and often the quality of the early preclinical or clinical data that investors receive is not robust. Dr. Tran is an experienced neuro-oncologist who understands how to develop a data package that will garner additional investment. I will be happy to review the data generated from this project to consider funding the technology further.

Best,



Laura Tadvalkar, Ph.D.
Managing Director, RA Capital Management